Metotab (Methotrexate Disodium)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing tetrahydrofolate production and thereby limiting the synthesis of DNA, RNA and proteins. This hampers the growth of rapidly dividing cells and also increases extracellular adenosine, which provides anti‑inflammatory effects.

The exact dose of Metotab is determined by the prescribing clinician based on the specific indication, patient weight, renal function and response to therapy. Dosage regimens are individualized and should follow the prescriber’s instructions.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in breast milk.

To request Metotab, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with biologic agents, methotrexate is a small‑molecule antimetabolite that can be taken orally and is generally less expensive. It has a well‑established efficacy profile for rheumatoid arthritis and psoriasis, but may require more laboratory monitoring for toxicity than some newer biologics.

Metotab should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Metotab is taken orally, usually with a full glass of water. Depending on the prescribing regimen, it may be taken once weekly or as directed by the healthcare provider. Patients should follow the specific timing and any dietary instructions given by their clinician.

The most serious risks include bone‑marrow suppression leading to anemia or infection, severe liver toxicity, pulmonary fibrosis or pneumonitis, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these symptoms develop.

Metotab should not be used by pregnant or breastfeeding women, patients with severe renal or hepatic impairment, those with known hypersensitivity to methotrexate, or individuals receiving live vaccines. It is also contraindicated in patients with active infections that could be worsened by immunosuppression.